Presently, two phase I clinical trials have published interim results: one evaluates autologous GD2-CAR NKT cells with IL-15 in children with relapsed or resistant neuroblastoma (NCT03294954), while the other focuses on allogeneic CD19-CAR NKT cells with IL-15 targeting relapse and refractory B cell malignancies (NCT03774654). Here, CD19 is linked to neuroblastoma.